Imatinib
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Imatinib: From Chronic Myeloid Leukaemia/GIST to Heart Fibrosarcoma
One-Sentence Summary
Imatinib is a tyrosine kinase inhibitor originally developed for chronic myeloid leukaemia (CML) and gastrointestinal stromal tumours (GIST). The TxGNN model predicts it may be effective for Heart Fibrosarcoma, but this direction is currently supported by 0 clinical trials and only 1 publication, and that publication’s own title states the new indications lack robust evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Chronic Myeloid Leukaemia (CML) / Gastrointestinal Stromal Tumours (GIST) |
| Predicted New Indication | Heart Fibrosarcoma |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L4 |
| EU Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for this candidate is not available from the structured drug record (DrugBank query returned no MOA text). Based on information present elsewhere in this evidence pack, Imatinib is a small-molecule tyrosine kinase inhibitor acting on BCR-ABL, KIT, and PDGFR, and its efficacy in CML and GIST is well established and clinically proven.
The proposed link to heart fibrosarcoma is an extension of Imatinib’s known activity against PDGFR/KIT-driven fibroblastic and mesenchymal tumour lineages (the same biology underlying its approved use in dermatofibrosarcoma protuberans) to a cardiac anatomical location. However, this is a mechanistic inference rather than a demonstrated effect: there is no cardiac-specific trial or case data, and the single supporting publication is itself a review whose title explicitly frames newer Imatinib indications as lacking robust evidence. The prediction should therefore be read as biologically plausible but mechanistically indirect and clinically unproven.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 18623899 | 2008 | Review | Prescrire international | Reviews Imatinib’s expanding indications beyond CML/GIST (e.g., Philadelphia chromosome-positive ALL), noting that while some non-comparative trial data exist, evidence for newer indications remains inconclusive rather than robust. |
EU Market Information
This product currently holds no EU marketing authorization (market status: Not Marketed; 0 authorizations on record).
Cytotoxicity
Imatinib is an antineoplastic agent (originally indicated for CML and GIST), so this section applies.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (tyrosine kinase inhibitor targeting BCR-ABL/KIT/PDGFR) |
| Myelosuppression Risk | Please refer to the SmPC warnings and precautions |
| Emetogenicity Classification | Please refer to the SmPC warnings and precautions |
| Monitoring Items | Please refer to the SmPC warnings and precautions |
| Handling Protection | Please refer to the SmPC warnings and precautions |
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for heart fibrosarcoma rests on a single review-level publication with no direct clinical trial or case-level evidence, and that publication itself describes the broader class of newer Imatinib indications as lacking robust support. The mechanistic link is inferred by extension from other fibroblastic tumour types rather than demonstrated for the cardiac site specifically.
To proceed, the following is needed:
- TFDA/EMA label warnings and contraindications (currently a blocking data gap, DG001) before any safety evaluation can proceed
- Confirmed mechanism of action data from DrugBank (DG002), to properly assess mechanistic relevance to heart fibrosarcoma
- Cardiac-specific case reports, case series, or a dedicated trial to move beyond model-prediction-only status
- Drug-drug interaction data (current DDI query returned no results)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.